Peregrine Pharmaceuticals Inc. shares fell in the extended session Friday after the biotech drug company's quarterly results fell short of Wall Street estimates. Peregrine shares fell 13% to $4.85 after hours. The company reported a fiscal fourth-quarter loss of 16 cents a share on revenue of $17.9 million. Analysts surveyed by FactSet had forecast a loss of 4 cents a share on revenue of $22.6 million.
Continue Reading Below
Copyright © 2017 MarketWatch, Inc.